

20 July 2016

ASX Code: MXC

## Q&A with Dr Ross Walker, MGC Pharmaceuticals Director

MGC Pharmaceuticals Ltd (ASX:MXC or “the Company”) is pleased to advise MXC shareholders of the Finfeed publication of a Q&A article with Non-Executive Director and Chairman of the Strategic Advisory Board, Dr Ross Walker, on the benefits of medicinal cannabis.

The Q&A article is available to be viewed via a link on the Company’s website:

<http://mgcpharma.com.au/#MediaNews>

-Ends-

### For further information, please contact:

#### Media Enquiries

Andrew Ramadge  
Senior Account Manager  
Media and Capital Partners  
+61 475 797 471  
[andrew.ramadge@mcpartners.com.au](mailto:andrew.ramadge@mcpartners.com.au)

#### MGC Pharmaceuticals Ltd

Brett Mitchell  
Executive Chairman  
+61 8 9389 2000  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

### About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value add industries, as demonstrated with MGC Derma Anti-Aging line of Cannabidiol-based (CBD) cosmetics.